18 July 2018
Polares Medical SA, in Ecublens near Lausanne, a preclinical stage medical technology company focused on the development of a unique trans-catheter mitral valve hemi-replacement system to treat patients suffering from mitral regurgitation (MR), closed a USD 25 million financing led by Decheng Capital (Menlo Park and Shanghai), with the participation of Endeavour Vision (Geneva), IDO Investments (Muscat), Earlybird Venture Capital (Berlin) and Wellington Partners (Munich).
VISCHER AG advises Polares since foundation; the team is led by Dr. Matthias Staehelin (Partner, Corporate) with Vincent Reardon and Luzius Zumstein (both Associates, Corporate).